NEW YORK (GenomeWeb News) – The DNA Repair Company has licensed the exclusive North American rights to a test from Helsinki University Central Hospital that predicts how women with breast cancer will respond to a common chemotherapy drug.
The Boston-based company acquired the rights to the test through an agreement with Licentia, a Finnish technology transfer company. DNAR plans to use a variant of the NQO1 enzyme to create personalized medicine tests.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.